Literature DB >> 9075097

Slipped capital femoral epiphysis associated with renal failure osteodystrophy.

R T Loder1, R N Hensinger.   

Abstract

A retrospective institutional and literature review of 31 children (20 boys and 11 girls) with 58 renal failure-associated slipped capital femoral epiphyses (RFASCFEs) was performed. The average age at diagnosis of renal failure was 8.9 years, and for RFASCFE 11.5 years, with a linear correlation between these two ages. All patients had secondary hyperparathyroidism at diagnosis of the RFASCFE. The median height and weight were below the 5th percentile. The RFASCFEs were stable and bilateral in 95% of the children. Slip magnitude was mild in 53%, moderate in 8%, and severe in 39%. Avascular necrosis was associated with steroid immunosuppression in children with renal transplants. All children were treated with medical management; surgery was used in an additional 29 hips. If correction of secondary hyperparathyroidism is not achieved within 2 months, RFASCFEs are likely to progress and surgical stabilization is recommended.

Entities:  

Mesh:

Year:  1997        PMID: 9075097     DOI: 10.1097/00004694-199703000-00013

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  15 in total

1.  Subclinical bilateral involvement of the hip in patients with slipped capital femoral epiphysis: a multicentre study.

Authors:  Yusuke Kohno; Yasuharu Nakashima; Toshio Kitano; Tomoyuki Nakamura; Kazuyuki Takamura; Mio Akiyama; Daisuke Hara; Takuaki Yamamoto; Goro Motomura; Masanobu Ohishi; Satoshi Hamai; Iwamoto Yukihide
Journal:  Int Orthop       Date:  2013-10-11       Impact factor: 3.075

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Bilateral slipped capital femoral epiphysis in a male adolescent with familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), chronic renal failure, and severe hyperparathyroidism.

Authors:  Przemysław Sikora; Małgorzata Zajączkowska; Tomasz Raganowicz; Halina Borzęcka; Andrzej Gregosiewicz; Martin Konrad
Journal:  Eur J Pediatr       Date:  2013-03-03       Impact factor: 3.183

4.  Increased acetabular depth may influence physeal stability in slipped capital femoral epiphysis.

Authors:  David A Podeszwa; David Gurd; Anthony Riccio; Adriana De La Rocha; Daniel J Sucato
Journal:  Clin Orthop Relat Res       Date:  2013-01-26       Impact factor: 4.176

5.  Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.

Authors:  G Klaus; A Watson; A Edefonti; M Fischbach; K Rönnholm; F Schaefer; E Simkova; C J Stefanidis; V Strazdins; J Vande Walle; C Schröder; A Zurowska; M Ekim
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

Review 6.  The epidemiology and demographics of slipped capital femoral epiphysis.

Authors:  Randall T Loder; Elaine N Skopelja
Journal:  ISRN Orthop       Date:  2011-09-21

7.  The alpha angle as a predictor of contralateral slipped capital femoral epiphysis.

Authors:  Matthew J Boyle; Jose F Lirola; Grant D Hogue; Yi-Meng Yen; Michael B Millis; Young-Jo Kim
Journal:  J Child Orthop       Date:  2016-04-06       Impact factor: 1.548

Review 8.  Treatment of stable slipped capital femoral epiphysis: systematic review and exploratory patient level analysis.

Authors:  H Naseem; S Chatterji; K Tsang; M Hakimi; A Chytas; S Alshryda
Journal:  J Orthop Traumatol       Date:  2017-08-22

9.  Slipped capital femoral epiphysis: a population-based study.

Authors:  Bengt Herngren; Margaretha Stenmarker; Ludek Vavruch; Gunnar Hagglund
Journal:  BMC Musculoskelet Disord       Date:  2017-07-18       Impact factor: 2.362

10.  Acetabular morphology in slipped capital femoral epiphysis: comparison at treatment onset and skeletal maturity.

Authors:  D A Maranho; A Davila-Parrilla; P E Miller; Y-J Kim; E N Novais; M B Millis
Journal:  J Child Orthop       Date:  2018-10-01       Impact factor: 1.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.